A5081028472- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Ubiquitin and proteasome pathways
- Eosinophilic Disorders and Syndromes
- Protein Degradation and Inhibitors
- Cancer-related Molecular Pathways
- Immune Cell Function and Interaction
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- RNA Interference and Gene Delivery
- Multiple Myeloma Research and Treatments
- Cell Image Analysis Techniques
- Histone Deacetylase Inhibitors Research
- HER2/EGFR in Cancer Research
- Epigenetics and DNA Methylation
- Peptidase Inhibition and Analysis
- interferon and immune responses
- Acute Lymphoblastic Leukemia research
- Medical Imaging Techniques and Applications
- RNA modifications and cancer
- RNA Research and Splicing
- Glycosylation and Glycoproteins Research
University of Freiburg
2015-2024
University Medical Center Freiburg
2014-2024
Deutschen Konsortium für Translationale Krebsforschung
2018-2024
German Cancer Research Center
2016-2024
Heidelberg University
2016-2024
University of Tsukuba Hospital
2019
University of Tsukuba
2019
Memorial Sloan Kettering Cancer Center
2012-2018
University of Lübeck
2018
Cold Spring Harbor Laboratory
2007-2013
Oncogenic JAK mutation sensitizes myeloproliferative neoplasms to immune checkpoint inhibition.
Anaplastic thyroid carcinoma (ATC) and metastatic poorly differentiated carcinomas (PDTCs) are rare aggressive malignancies with poor overall survival (OS) despite extensive multimodal therapy. These tumors highly proliferative, frequently increased tumor mutational burden (TMB) compared carcinomas, elevated programmed death ligand 1 (PD-L1) levels. properties implicate responsiveness to antiangiogenic antiproliferative multikinase inhibitors such as lenvatinib, immune checkpoint pembrolizumab.
Dramatic advances in our understanding of the molecular pathophysiology cancer, along with a rapidly expanding portfolio targeted drugs, have led to paradigm shift toward personalized, biomarker-driven cancer treatment. Here, we report 2-year experience Comprehensive Cancer Center Freiburg Molecular Tumor Board (MTB), one first interdisciplinary tumor conferences established Europe. The role MTB is recommend personalized therapy for patients beyond standard-of-care
Abstract Successful treatment of acute myeloid leukemia (AML) with chimeric antigen receptor (CAR) T cells is hampered by toxicity on normal hematopoietic progenitor and low CAR cell persistence. Here, we develop third-generation anti-CD123 a humanized CSL362-based ScFv CD28-OX40-CD3ζ intracellular signaling domain. This demonstrates anti-AML activity without affecting the healthy system, or causing epithelial tissue damage in xenograft model. CD123 expression increases upon 5′-Azacitidine...
Molecular precision oncology faces two major challenges: first, to identify relevant and actionable molecular variants in a rapidly changing field second, provide access broad patient population. Here, we report four-year experience of the Tumor Board (MTB) Comprehensive Cancer Center Freiburg (Germany) including workflows process optimizations. This retrospective single-center study includes data on 488 patients enrolled MTB from February 2015 through December 2018. Recommendations include...
The human interleukin(IL)-18 is a key regulator of interferon(IFN)-gamma production and T-cell differentiation. Here we report the complete genomic structure characterization 5'untranslated promoter region IL-18 gene. gene composed six exons five introns, spanning approximately 19. 5kb. Promoter activity 5'-flanking was investigated with luciferase reporter assay. Transient transfection studies demonstrate constitutive expression in monocytic U937 THP-1 cells. For this at least 92 base pairs...